Professur für Dermatologie

Impairment of gustatory and olfactory senses in plaque psoriasis (2017) Rueter P, Gruenthaler V, Zopf Y, Sticherling M Conference contribution Comparative analysis of human dendritic cell subpopulations in steady state and inflammation (2017) Heger L, Heidkamp GF, Lehmann C, Eissing N, Söder S, Hartmann A, Zenk J, et al. Conference contribution Doxycycline versus Prednisolone for the initial Treatment of bullous Pemphigoids: a pragmatic prospective randomized Study (2017) Schmidt E, Benoit S, Ehrchen J, Glaeser R, Guenther C, Steinbrink K, Sticherling M, et al. Conference contribution Fumaric Acid Esters and TNF alpha Inhibitors - Do they affect the Fertility of male Patients with Psoriasis? (2017) Heppt F, Colsmann A, Maronna A, Uslu U, Heppt M, Kiesewetter F, Sticherling M Conference contribution Fumaric Acid Esters: Patient Characteristics and Duration of Therapy from the PsoBest German Psoriasis Registry (2017) Augustin M, Reich K, Spehr C, Rustenbach SJ, Mrowietz U, Radtke MA, Wilsman-Theis D, et al. Conference contribution Hydradenitis suppurativa - new exploration on the famous Disease (2017) Oetterich K, Heppt F, Sticherling M Conference contribution Secukinumab Treatment of moderate to severe Plaque Psoriasis in the clinical Routine Care: Baseline Data from the PROSPECT Study on Psoriasis Pre-treatment (2017) Von Kiedrowski R, Korber A, Kraehn-Senftleben G, Sticherling M, Lange L, Bachhuber T, Kasparek TR, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without previous Systemic Therapy for Improvement of Skin Symptoms: PASI and IGA mod. 2011-Results of the PRIME Study (2017) Reich K, Mrowietz U, Augustin M, Thaci D, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with respect to the Improvement of quality of life: DLQI and SF-36 Results of the PRIME Study (2017) Augustin M, Thaci D, Reich K, Mrowietz U, Kneidl J, Hentschke C, Simang M, et al. Conference contribution Secukinumab is superior to Fumaric Acid Esters in the Treatment of Patients with moderate to severe Plaque Psoriasis without prior System Therapy with regard to compatibility-related Therapeutic Adherence: Safety Results of the PRIME Study (2017) Mrowietz U, Augustin M, Thaci D, Reich K, Kneidl J, Hentschke C, Simang M, et al. Conference contribution